Chymotrypsinogen/trypsinogen - Propanc

Drug Profile

Chymotrypsinogen/trypsinogen - Propanc

Alternative Names: PRP; PRP-DCP; PRP-Injection

Latest Information Update: 04 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Propanc Health Group Corporation
  • Developer Propanc Biopharma
  • Class Antineoplastics; Enzyme precursors; Serine endopeptidases
  • Mechanism of Action PAR-2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Colorectal cancer; Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 02 Aug 2017 Propanc plans to submit application to US FDA seeking Orphan Drug designation for Ovarian Cancer in August 2017
  • 20 Jul 2017 Chymotrypsinogen/trypsinogen receives patent allowance for PRP in China
  • 26 Jun 2017 Chymotrypsinogen/trypsinogen receives Orphan Drug status for Pancreatic cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top